BACKGROUND: Many patients with castration-resistant prostate cancer suffer from local disease progression, mostly consisting of subvesical obstruction, gross haematuria and rectal invasion with obstructive ileus. We analysed the benefit of palliative radical surgery in this patient cohort. MATERIAL AND METHOD: Between 2004 and 2010, 20 patients underwent radical surgery; 12 patients underwent radical cystoprostatectomy, 3 patients required additional rectal resection and 4 patients were treated by radical prostatectomy. One patient with a poor prognosis received an ureterocutaneostomy and a colostomy. In all other patients an ileal conduit was chosen for urinary diversion. RESULTS: The reduction of symptoms could be achieved in 16 of 20 (80%) patients. The median symptom-free survival was 15.3 (6-25) months, and median survival was 20.3 (9-28) months. CONCLUSION: With radical tumour surgery an effective local symptom control can be achieved. This individual therapeutic concept should be discussed in highly selected patients.
BACKGROUND: Many patients with castration-resistant prostate cancer suffer from local disease progression, mostly consisting of subvesical obstruction, gross haematuria and rectal invasion with obstructive ileus. We analysed the benefit of palliative radical surgery in this patient cohort. MATERIAL AND METHOD: Between 2004 and 2010, 20 patients underwent radical surgery; 12 patients underwent radical cystoprostatectomy, 3 patients required additional rectal resection and 4 patients were treated by radical prostatectomy. One patient with a poor prognosis received an ureterocutaneostomy and a colostomy. In all other patients an ileal conduit was chosen for urinary diversion. RESULTS: The reduction of symptoms could be achieved in 16 of 20 (80%) patients. The median symptom-free survival was 15.3 (6-25) months, and median survival was 20.3 (9-28) months. CONCLUSION: With radical tumour surgery an effective local symptom control can be achieved. This individual therapeutic concept should be discussed in highly selected patients.
Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin Journal: JAMA Date: 2005-07-27 Impact factor: 56.272
Authors: Martin Spahn; Christel Weiss; Pia Bader; Philipp Ströbel; Elmar W Gerharz; Burkard Kneitz; Detlef Frohneberg Journal: Urol Int Date: 2010-03-04 Impact factor: 2.089
Authors: Dan Leibovici; Ashish M Kamat; Curtis A Pettaway; Lance Pagliaro; Charles J Rosser; Christopher Logothetis; Louis L Pisters Journal: J Urol Date: 2005-12 Impact factor: 7.450
Authors: Daher C Chade; Shahrokh F Shariat; Angel M Cronin; Caroline J Savage; R Jeffrey Karnes; Michael L Blute; Alberto Briganti; Francesco Montorsi; Henk G van der Poel; Hendrik Van Poppel; Steven Joniau; Guilherme Godoy; Antonio Hurtado-Coll; Martin E Gleave; Marcos Dall'Oglio; Miguel Srougi; Peter T Scardino; James A Eastham Journal: Eur Urol Date: 2011-03-21 Impact factor: 20.096
Authors: Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Andrew J Stephenson; Peter T Scardino; Fernando J Bianco; Christopher J DiBlasio; Paul A Fearn; James A Eastham Journal: J Urol Date: 2004-12 Impact factor: 7.450
Authors: Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock Journal: J Clin Oncol Date: 2008-01-10 Impact factor: 44.544